Overview of Persil

Quick Facts

Property	Description
Active ingredient	Naphazoline Hydrochloride, Chlorpheniramine Maleate
Form	Sterile Ophthalmic Solution (Eye Drop)
Pharmacological class	Ophthalmic Decongestant and Antihistamine Combination
Common purpose	Symptomatic relief of eye redness and irritation
Origin	Synthetic

Defining Persil: Identity, Form, and General Purpose

Persil is a synthetic, multi-ingredient sterile ophthalmic solution administered as an eye drop for topical ocular use. It is formally classified under the WHO's Anatomical Therapeutic Chemical (ATC) system as an Ophthalmic Decongestant and Antihistamine Combination (WHO ATC Code S01GA01). Its general purpose is the symptomatic management of acute eye irritation, visible redness, and discomfort caused by minor environmental irritants and common allergens. Unlike preparations containing only a decongestant or a simple saline base, this combination product is designed for initial, broad-spectrum relief when symptoms involve both vascular congestion and an allergic component.

The Pharmacological Profile and Active Ingredients

The unique function of Persil is derived from its key chemical components. The main active ingredient is Naphazoline Hydrochloride, an imidazoline derivative that acts as an alpha-adrenergic agonist. This component works by constricting localized blood vessels to relieve redness. It is combined with Chlorpheniramine Maleate, a first-generation antihistamine, which is included to block the effects of histamine and relieve allergic symptoms like itching. The formulation also typically includes Zinc Sulfate, which offers a mild astringent effect that is useful for soothing the eye surface when environmental exposure has caused irritation. This multi-agent strategy is a distinguishing characteristic, providing dual action against both vascular congestion and histamine release.

What side effects are possible with Persil?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics for this ophthalmic solution (Naphazoline Hydrochloride and Chlorpheniramine Maleate combination) as defined in government regulatory documents.

Ocular and Systemic Reactions

The adverse reaction profile includes both localized Eye Disorders and potential Systemic Effects resulting from the absorption of the active ingredients. Ocular effects may include eye irritation, eye pain, and temporary mydriasis (pupil enlargement). Systemic effects may involve Nervous System Disorders (such as headache and dizziness) and effects on the Cardiovascular System (such as cardiac irregularities and hypertension).

Many adverse reactions documented in the post-marketing setting are categorized by some national regulatory authorities as Frequency Not Known, meaning their occurrence rate cannot be estimated from available data. Hypersensitivity reactions are also officially listed as a possible adverse reaction.

Exposure- and Population-Related Safety

Safety Domain	Regulatory Statement Context
Time-Related Pattern	The official label documents the risk of rebound conjunctival hyperaemia (increased redness) associated with the overuse or long-term administration of the product.
Pediatric Toxicity	Serious Adverse Reactions are specifically documented regarding accidental oral ingestion in infants and children, which may lead to coma and marked reduction in body temperature. Safety for use in pediatric patients has not been established.

Safety Restrictions and Limitations

Use of this solution is strictly contraindicated in the presence of an anatomically narrow angle or established narrow-angle glaucoma. Caution is also required in individuals with pre-existing conditions such as hypertension, severe cardiovascular abnormalities, hyperglycemia (diabetes), or hyperthyroidism. Furthermore, the official label notes the potential for a severe hypertensive crisis in individuals receiving concurrent treatment with MAO inhibitors.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Persil primarily address the risks associated with systemic absorption following accidental oral ingestion of the ophthalmic solution. These documents indicate that an overdose can lead to serious and potentially life-threatening adverse events.

Documented Clinical Manifestations

Systemic toxicity typically presents as profound CNS depression, which may include lethargy, somnolence, stupor, and severe weakness. Other documented physiological findings include a marked reduction in body temperature (hypothermia), and cardiovascular effects such as a slow heart rate (bradycardia) and blood pressure changes.

Mandatory Emergency Action

Regulatory labeling mandates that in the event of any suspected or known accidental ingestion, you must seek professional assistance or contact a Poison Control Center immediately. Due to the risk of serious outcomes, particularly coma and respiratory depression, official guidance requires that you seek emergency medical care immediately.

Population-Specific Risk and Management

The highest risk for life-threatening events is specifically noted in infants and children, ages 5 years and younger. Management involves providing symptomatic and supportive treatment, as the official prescribing information does not document a specific pharmacological antidote. Prolonged medical observation or hospitalization may be required for monitoring the progression of systemic symptoms.

Therapeutic Uses of Persil

What Persil Treats: Main Uses and Benefits

Persil is commonly used for the symptomatic management of acute, mild to moderate eye conditions characterized by heightened discomfort and visible irritation. Its therapeutic utility is focused on providing temporary relief across key symptomatic domains associated with common external and allergic triggers. As an established over-the-counter (OTC) combination, it is commonly used to help with temporary relief of symptoms caused by pollen, ragweed, grass, animal hair, and dander.

It is relevant in situations where patients experience a pronounced cluster of symptoms, including ocular itching, watering (lacrimation), and visible redness (hyperemia).

Acute Relief from Allergic Ocular Symptoms

This domain covers the primary application for symptoms linked to an allergic response. The medication is applied in addressing symptom clusters that may become intense or disruptive, such as pronounced ocular itching and excessive watering. It may assist with maintaining a sense of stability when symptoms are more noticeable during difficult, acute allergic episodes.

Management of Visible Eye Redness and Congestion

This is used for managing symptoms related to heightened physiological activity. The medication contributes to easing the overall symptom load during periods of heightened symptoms. It is also used for the supportive management of general surface symptoms, including burning, smarting, or general discomfort, often triggered by acute exposure to irritants like wind, dust, or chlorine (from swimming).

Quick Fact: Relief for Acute Eye Discomfort

Symptom Category	Relief Focus	Clinical Context
Vascular	Reduces visible redness (hyperemia)	Acute exposure to irritants or allergens
Allergic	Manages itching (pruritus) and watering	Seasonal flare-ups or episodic exposure
Surface	Supports general comfort and addresses burning	Situations where supportive relief is appropriate

Regulatory References

NIH DailyMed database

Eligibility and Restrictions for Use

Persil laundry detergent is generally safe for its intended use, which is washing fabrics. However, as an industrially manufactured cleaning agent, it contains various chemicals—such as surfactants, enzymes, fragrances, and preservatives—that are known to be irritants or allergens for certain individuals.

Who Can Use Persil?

General Population: The product is designed for safe use by the general public when handled according to the instructions on the label (e.g., proper dilution, avoiding ingestion or eye contact).

Who Should Exercise Caution or Avoid Use?

Certain groups of people should take precautions or choose specific, gentler formulations, such as those labeled "Sensitive," which are often free of dyes and strong fragrances.

Population Group	Reason for Caution/Contraindication
Individuals with Sensitive Skin	Components like surfactants, dyes, and fragrances may trigger contact dermatitis, causing rashes, itching, or redness.
Individuals with Respiratory Conditions	Volatile compounds, particularly strong fragrances, may trigger symptoms like coughing, wheezing, or asthma attacks.
Children	The product should be stored out of reach of children due to the high risk of accidental ingestion or contact with the eyes, which can cause serious damage or chemical burns.
Individuals with Known Allergies	Should avoid use if they are allergic to specific ingredients found in the product, such as certain preservatives (e.g., Methylisothiazolinone) or fragrance compounds (e.g., Limonene, Linalool).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of this ophthalmic solution is primarily structured by the systemic absorption potential of the vasoconstrictor component, Naphazoline, and the resulting pharmacodynamic effects. Officially documented interactions in government regulatory labels establish a set of restrictions and mandatory administration requirements.

Contraindicated and Pharmacodynamic Drug Interactions

Interacting Substance Category	Regulatory Classification	Official Interaction Description
Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated Combination	Co-administration is formally prohibited due to the risk of a severe hypertensive reaction.
Tricyclic Antidepressants (TCAs)	Pharmacodynamic Interaction	Risk of potentiation of the decongestant's systemic effects.
Drugs for High Blood Pressure	Pharmacodynamic Interaction	Potential for reduced effectiveness of the antihypertensive medication.

Other Interaction Requirements

The official labeling also documents a procedural interaction constraint concerning medical products co-administered to the eye. Soft contact lenses must be removed immediately before using the drops and are required to be kept out for a minimum of 10 to 15 minutes after instillation. This measure addresses the interaction between the product's preservative and the lens material.

No clinically relevant pharmacokinetic, food, alcohol, or herbal supplement interactions are formally documented in the current regulatory labels for this specific ophthalmic product.

Mechanism of Action

The drug's mechanism operates through three distinct, concurrent pharmacological actions. Naphazoline initiates a signaling sequence via agonism at Alpha-1 (alpha1) adrenergic receptors on ocular arteriolar smooth muscle. This alpha1 activation causes the arterioles to constrict, leading to a rapid reduction in local blood volume and mitigation of tissue engorgement. Concurrently, Chlorpheniramine operates within the Histamine-Mediated Inflammatory Pathway by acting as a competitive antagonist at Histamine H1 receptors (mathrmH1). This mathrmH1 blockade limits the propagation of signaling associated with pruritus and inhibits the histamine-driven increase in vascular permeability. The third component, Zinc Sulfate, provides a distinct physical action through surface protein astringency. This integrated, synergistic mechanism addresses both the physical vascular volume and the underlying mediator response, contributing to the constraint of dysregulated signaling and local fluid extravasation across the targeted ocular pathways.

Dosage and Administration Information

The official use of Persil, designated as a laundry detergent, is strictly for fabric treatment via washing machines or hand washing, and uses other than those specified are not recommended. Proper administration is dependent on the product form (liquid, powder, or single-dose packets) and load conditions. The product is intended for dispensing into wash water, and is compatible with all washing machine types, including top-loading, front-loading, and high-efficiency (HE) washers.

Administration Guidance

Administration Parameter	General Use Guidance (Based on Liquid Detergent)
Route of Administration	Addition to wash water or machine dispenser.
Dosing Schedule	Regular Loads: Fill cap to line 2 (approx. 46.1 mL). Large/Heavy Soil: Fill cap to line 4 (approx. 73.9 mL).
Timing/Frequency	As-needed for laundry; effective in all water temperatures, including cold.
Preparation	Liquid detergent is ready-to-use. For stain pre-treatment, a small amount may be applied directly to the stain and rubbed gently into the fabric before washing.
Age-Group Rule	Keep out of reach of children.
Missed-Use	Not applicable (product is used on an as-needed basis).

Procedural Sequence: The official use protocol involves sorting the laundry, optionally pre-treating stains, measuring the required dosage based on load size and soil level, and adding the product to the appropriate dispenser compartment or directly to the drum (for certain top-load machines) before initiating the wash cycle.

Recent Clinical Evidence

Research evidence / Overview of Studies for Persil

This section summarizes the types of research that have explored the use of the combination ophthalmic solution (containing both a decongestant and an antihistamine) and describes the context of the evidence, including what remains uncertain.

Evidence for Use in Acute Allergic Conjunctivitis Symptoms

The evidence for this combination product was primarily evaluated in short-term randomized controlled trials (RCTs). Research explored outcomes related to physical discomfort in studies conducted during periods of increased symptom activity. The focus was primarily on measuring patient-reported outcomes describing perceived discomfort, such as ocular itching and tearing, alongside objective signs like visible eye redness (hyperemia) and swelling.

Key research scenarios often include the Conjunctival Allergen Challenge (CAC) model. This controlled setting allows researchers to induce a standardized allergic reaction and then study patterns over defined time intervals. Studies monitored these outcomes to describe the patterns observed in the studies. These studies contribute to the broader evidence landscape, particularly concerning changes measured over defined time intervals.

Evidence for Use in Non-Allergic Ocular Redness and Irritation

The research exploring conditions characterized by physical discomfort not linked to allergies was evaluated using the evidence profile of the decongestant component, Naphazoline, as outlined in regulatory monographs. Studies explored how the decongestant component was observed in research examining temporary physiological imbalance. Outcomes observed in this context include the reduction of visible redness and the change in patient-reported outcomes describing perceived discomfort.

Research on Long-Term Outcomes and Extended Use

The research for this combination product was evaluated in studies conducted during periods of increased symptom activity; evidence for long-term effects are not fully established. A recognized research limitation associated with the decongestant component is the potential for rebound hyperemia or tachyphylaxis. Research primarily observes responses over defined, short time intervals, and there is limited information for long-term outcomes or durability of effect beyond a few days.

Evidence in Special Populations

Data for certain groups remain insufficient, as many core efficacy studies were conducted on healthy, non-elderly adults. Studies exploring patient-reported outcomes describing perceived discomfort remain insufficient in children under the age of 12 years. Data for older adults, particularly those with existing cardiovascular conditions, remain insufficient due to concerns that systemic absorption may be associated with physiological strain. Thus, subgroup findings are uncertain for this population.

Key Studies & References

Chlorpheniramine: MedlinePlus Drug Information (citing contraindications and systemic absorption risk in children/elderly)

Frequently Asked Questions (FAQ)

Common questions about Persil (FAQ)

Q: How quickly does Persil start to work?

A: Official information indicates that Naphazoline, the decongestant component, constricts blood vessels through a rapid mechanism involving alpha-adrenergic receptors. This process is associated with a rapid mechanism intended to reduce local blood volume and mitigate visible redness.

Q: Is Persil the same as [Generic Drug Name]?

A: The active ingredients in the Persil ophthalmic solution are Naphazoline Hydrochloride and Chlorpheniramine Maleate. This combination is available both under various brand names and as a generic, unbranded product.

Q: Can older adults use Persil?

A: Official regulatory documents describe a need for caution related to use in older adults, especially those with pre-existing conditions like high blood pressure (hypertension) or certain cardiovascular abnormalities. This relates to the potential for systemic effects from the decongestant component.

Q: What are the most serious side effects listed for Persil?

A: Systemic reactions that have been reported from official post-marketing data include effects on the cardiovascular system such as hypertension (high blood pressure) and cardiac irregularities. Other reported systemic effects include dizziness, headache, and nervousness.

Q: Why is Persil not recommended for people with [Specific Organ Condition]?

A: The product is strictly contraindicated (should not be used) if an individual has narrow-angle glaucoma. Caution is also advised in official labeling for people with high blood pressure, heart disease, or trouble urinating due to an enlarged prostate gland. These cautions are linked to the properties of the decongestant ingredient and its potential for systemic effects.

Q: How long do I need to wait to see the full effect of Persil?

A: Official directions indicate that if eye redness or irritation worsens or persists for more than 72 hours, the product's use should be stopped. This 72-hour period serves as a practical timeframe for observing the expected effects of the solution.

Q: What age group is Persil typically approved for?

A: Official product information states that this solution is approved for use in adults and children 6 years of age and older. Safety and use have not been established for children under the age of 6, and the product's labeling advises speaking with a doctor for that population.

Q: How does the FDA classify Persil?

A: According to the official product information, this combination ophthalmic solution is classified as a Human Over-The-Counter (OTC) Drug. It is not considered a controlled medication by regulatory authorities.

Q: What are the potential signs of an allergic reaction to Persil?

A: Signs that may indicate a reaction include eye pain, changes in vision, or redness/irritation that worsens or persists past the expected treatment duration. Regulatory information includes a statement that the product should not be used by individuals sensitive to any of the ingredients.

Q: Can I get sick if I take an expired Persil tablet?

A: The product is a sterile ophthalmic solution (eye drop), not a tablet. Official storage information states the solution should not be used if it changes color or becomes cloudy. Official labeling states that the product must be stored and used before the expiration date marked on the carton or bottle.

Q: What are the official warnings about Persil and common cold or flu medicines?

A: Official warnings state that the product is strictly contraindicated (should not be used) in patients currently taking or who have recently stopped taking (within 14 days) Monoamine Oxidase Inhibitors (MAOIs). The restriction relates to the potential for severe reactions when the product is used concurrently with MAOIs.

Q: Is Persil available over the counter?

A: Yes, official product information classifies this combination ophthalmic solution as a Human Over-The-Counter (OTC) Drug, meaning it can be purchased without a prescription.

Q: Is Persil considered a narcotic?

A: No. According to the official classification, this product is an Over-The-Counter (OTC) medicine and is not classified as a controlled substance or narcotic.

Q: Is Persil safe to use during pregnancy, according to official sources?

A: Official labeling notes that animal studies have not been conducted and it is not known whether the ingredients can cause fetal harm. Official labeling states that the product should be used during pregnancy only when the potential benefit is considered to outweigh the potential risk, as determined by a healthcare provider.

Q: Is it safe to drive after taking Persil?

A: Reported side effects include dizziness and temporary pupil enlargement (mydriasis). Individuals should be mindful of these reported effects before engaging in activities that require full attention, such as driving or operating machinery.

Q: Is Persil a controlled substance?

A: No. Based on regulatory documents, this ophthalmic solution is classified as an Over-The-Counter (OTC) Drug and is not listed as a controlled medication.

Q: What if Persil doesn't seem to be working for me?

A: Official labeling indicates that if eye redness or irritation persists for more than 72 hours, the product's use should be stopped.

How should Persil be stored and disposed of?

Official Storage and Disposal Requirements

Persil ophthalmic solution must be stored and handled according to the instructions on its official regulatory labeling. The medicine requires storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage environments must keep from freezing and protect the product from direct heat and light. The container is required to be kept tightly closed to maintain product integrity, and the solution should not be used if it changes color or becomes cloudy. The medicine must be stored out of the reach and sight of children.

Disposal must align with official guidelines: unused or expired product should be discarded through a drug take-back program. If no program is available, the product must be mixed with an unappealing substance and sealed before being placed in household trash. Do not flush this medicine down a sink or toilet.

Persil